赵维超,樊世明

半乳糖凝集素-3（Galectin-3，Gal-3）是一种广泛表达的β-半乳糖苷结合蛋白，在细胞内和细胞外均具有重要生物学功能。近年来，Gal-3在心血管疾病发生与发展中的作用日益受到重视。研究表明，Gal-3通过调控炎症反应、促进心肌纤维化以及参与细胞外基质重塑，在心房颤动（AF）、心力衰竭（HF）、急性冠脉综合征（ACS）及动脉粥样硬化等多种心血管疾病中发挥关键作用。临床数据进一步提示，Gal-3水平不仅可作为相关心血管疾病的辅助诊断指标，还在预测疾病进展、再住院风险及全因死亡率方面具有独立预后价值，尤其在心力衰竭患者中表现突出。综上所述，Gal-3作为连接免疫炎症反应与心脏结构重塑的关键分子，其深入研究有望为心血管疾病的诊断、治疗及预后评估提供新的靶点与策略。

半乳糖凝集素-3；心房颤动；心力衰竭；急性冠脉综合征；动脉粥样硬化；心肌纤维化

[1] Sygitowicz,Grażyna et al.“The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.”Biomolecules vol.12,1 46.29 Dec.2021. [2] Cao,Zhan-Qi et al.“Research progress on the role of gal-3 in cardio/cerebrovascular diseases.”Biomedicine&pharmacotherapy= Biomedecine&pharmacotherapie vol.133(2021):111066. [3] Ho,Jennifer E et al.“Galectin 3 and incident atrial fibrillation in the community.”American heart journal vol.167,5(2014):729-34.e1. [4] Gurses,Kadri Murat et al.“Effects of persistent atrial fibrillation on serum galectin-3 levels.”The American journal of cardiology vol.115,5(2015):647-51. [5] Clementy,Nicolas et al.“Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation.”Scientific reports vol.6 34357.28 Sep.2016. [6] Oremus,Mark et al.“BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure.”Heart failure reviews vol.19,4(2014):471-505. [7] van Kimmenade,Roland R et al.“Utility of amino-terminal pro-brain natriuretic peptide,galectin-3,and apelin for the evaluation of patients with acute heart failure.”Journal of the American College of Cardiology vol.48,6(2006):1217-24. [8] Chen,Hongsen et al.“Circulating galectin-3 on admission and prognosis in acute heart failure patients:a meta-analysis.”Heart failure reviews vol.25,2(2020):331-341. [9] Agnello,Luisa et al.“Galectin-3 in acute coronary syndrome.”Clinical biochemistry vol.50,13-14(2017):797-803. [10] Maiolino,Giuseppe et al.“Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease.”Arteriosclerosis,thrombosis,and vascular biology vol.35,3(2015):725-32. [11] Vroegindewey,Maxime M et al.“Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission.”American heart journal vol.216(2019):143-146. [12] Goenka,Luxitaa et al.“Factors which Influence the Levels of ST-2,Galectin-3 and MMP-9 in Acute Coronary Syndrome.” Cardiovascular&hematological disorders drug targets vol.20,1(2020):64-73. [13] Djordjevic,Ana et al.“Genetic Variants in the Vicinity of LGALS-3 Gene and LGALS-3 mRNA Expression in Advanced Carotid Atherosclerosis:An Exploratory Study.”Journal of clinical laboratory analysis vol.30,6(2016):1150-1157. [14] Tian,Lei et al.“Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells.”Molecular medicine reports vol.12,4(2015):4995-5002. [15] Ou,Hsiu-Chung et al.“Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway.”Environmental toxicology vol.34,7(2019):825-835. [16] Wu,Alan H B.“Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure:Galectin-3 and Soluble ST2.”EJIFCC vol.23,3 98-102.12 Oct.2012. [17] Weir,Robin A,P等人“半乳糖凝集素-3和急性心肌梗死幸存者的心脏功能”.流通｡心力衰竭第6,3卷(2013年):492-8. [18] Falkenham,Alec et al.“Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis.”The American journal of pathology vol.185,4(2015):927-42.

点击下载PDF